NZ754291B2 - Composition for cough - Google Patents
Composition for cough Download PDFInfo
- Publication number
- NZ754291B2 NZ754291B2 NZ754291A NZ75429118A NZ754291B2 NZ 754291 B2 NZ754291 B2 NZ 754291B2 NZ 754291 A NZ754291 A NZ 754291A NZ 75429118 A NZ75429118 A NZ 75429118A NZ 754291 B2 NZ754291 B2 NZ 754291B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- polysaccharide
- fraction
- fractions
- cells
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 131
- 206010011224 Cough Diseases 0.000 title claims abstract description 29
- 150000004676 glycans Chemical class 0.000 claims abstract description 81
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 81
- 239000005017 polysaccharide Substances 0.000 claims abstract description 81
- 244000307697 Agrimonia eupatoria Species 0.000 claims abstract description 46
- 235000000125 common agrimony Nutrition 0.000 claims abstract description 44
- 235000006576 Althaea officinalis Nutrition 0.000 claims abstract description 40
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 40
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 40
- 235000001035 marshmallow Nutrition 0.000 claims abstract description 40
- 235000012907 honey Nutrition 0.000 claims abstract description 35
- 229920001864 tannin Polymers 0.000 claims abstract description 35
- 239000001648 tannin Substances 0.000 claims abstract description 35
- 235000018553 tannin Nutrition 0.000 claims abstract description 35
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract 5
- 241001307241 Althaea Species 0.000 claims description 37
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 29
- 102000004856 Lectins Human genes 0.000 claims description 22
- 239000002523 lectin Substances 0.000 claims description 22
- 108090001090 Lectins Proteins 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 19
- 239000003937 drug carrier Substances 0.000 claims description 18
- 239000000796 flavoring agent Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- 239000006188 syrup Substances 0.000 claims description 14
- 235000020357 syrup Nutrition 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 8
- 235000013824 polyphenols Nutrition 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 239000002562 thickening agent Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 235000005979 Citrus limon Nutrition 0.000 claims description 4
- 244000131522 Citrus pyriformis Species 0.000 claims description 4
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 4
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims description 4
- 206010070488 Upper-airway cough syndrome Diseases 0.000 claims description 3
- 208000017574 dry cough Diseases 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 240000005125 Myrtus communis Species 0.000 claims description 2
- 235000013418 Myrtus communis Nutrition 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 239000007968 orange flavor Substances 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 244000208874 Althaea officinalis Species 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 88
- 239000000523 sample Substances 0.000 description 55
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 40
- 230000000694 effects Effects 0.000 description 39
- 230000004888 barrier function Effects 0.000 description 38
- 239000000047 product Substances 0.000 description 37
- 238000003556 assay Methods 0.000 description 36
- 241001127637 Plantago Species 0.000 description 35
- 239000003795 chemical substances by application Substances 0.000 description 32
- 239000002158 endotoxin Substances 0.000 description 27
- 229920006008 lipopolysaccharide Polymers 0.000 description 27
- 230000002757 inflammatory effect Effects 0.000 description 26
- 210000004379 membrane Anatomy 0.000 description 25
- 239000012528 membrane Substances 0.000 description 25
- 239000000126 substance Substances 0.000 description 25
- 230000003232 mucoadhesive effect Effects 0.000 description 20
- 150000003254 radicals Chemical class 0.000 description 19
- 102000004889 Interleukin-6 Human genes 0.000 description 18
- 108090001005 Interleukin-6 Proteins 0.000 description 18
- 210000004400 mucous membrane Anatomy 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 238000010790 dilution Methods 0.000 description 17
- 239000012895 dilution Substances 0.000 description 17
- 102000004127 Cytokines Human genes 0.000 description 16
- 108090000695 Cytokines Proteins 0.000 description 16
- 230000009471 action Effects 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 229940100601 interleukin-6 Drugs 0.000 description 16
- 230000003064 anti-oxidating effect Effects 0.000 description 15
- 238000000605 extraction Methods 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 229930003268 Vitamin C Natural products 0.000 description 13
- 210000003097 mucus Anatomy 0.000 description 13
- 239000013641 positive control Substances 0.000 description 13
- 235000019154 vitamin C Nutrition 0.000 description 13
- 239000011718 vitamin C Substances 0.000 description 13
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 12
- 239000002516 radical scavenger Substances 0.000 description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 230000036542 oxidative stress Effects 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 10
- 239000012530 fluid Substances 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 210000002345 respiratory system Anatomy 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 102000003992 Peroxidases Human genes 0.000 description 8
- 108010090804 Streptavidin Proteins 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 108040007629 peroxidase activity proteins Proteins 0.000 description 8
- 230000003068 static effect Effects 0.000 description 8
- 102000003886 Glycoproteins Human genes 0.000 description 7
- 108090000288 Glycoproteins Proteins 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 229960005070 ascorbic acid Drugs 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 238000001694 spray drying Methods 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000003238 esophagus Anatomy 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- -1 elixir Substances 0.000 description 5
- 239000003172 expectorant agent Substances 0.000 description 5
- 239000010408 film Substances 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 229930182478 glucoside Natural products 0.000 description 4
- 150000008131 glucosides Chemical class 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000012499 inoculation medium Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000000622 irritating effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000003684 drug solvent Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000001524 infective effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 230000000510 mucolytic effect Effects 0.000 description 3
- 229940066491 mucolytics Drugs 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 229940125723 sedative agent Drugs 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 239000000120 Artificial Saliva Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000008472 epithelial growth Effects 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 229940066493 expectorants Drugs 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 239000000399 hydroalcoholic extract Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000005550 inflammation mediator Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000002973 irritant agent Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000008146 mannosides Chemical group 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229940079877 pyrogallol Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000016993 Agrimonia Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 244000045232 Canavalia ensiformis Species 0.000 description 1
- 235000010520 Canavalia ensiformis Nutrition 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 235000015001 Cucumis melo var inodorus Nutrition 0.000 description 1
- 240000002495 Cucumis melo var. inodorus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 101100440286 Mus musculus Cntrl gene Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 244000239204 Plantago lanceolata Species 0.000 description 1
- 235000010503 Plantago lanceolata Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1h-imidazol-2-yl)quinoline-3-carboxylate Chemical compound N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000254 ciliated cell Anatomy 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000012505 colouration Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000009748 deglutition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- VZPGINJWPPHRLS-UHFFFAOYSA-N phenazine-2,3-diamine Chemical compound C1=CC=C2N=C(C=C(C(N)=C3)N)C3=NC2=C1 VZPGINJWPPHRLS-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 238000012496 stress study Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000000294 tussive effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Abstract
The present invention relates to a new composition for use in the treatment of cough comprising one or more polysaccharide fractions of plantain, one or more polysaccharide fractions of marshmallow, honey, brown sugar, one or more polyphenolic fractions of agrimony comprising tannins.
Description
COMPOSITION FOR COUGH DESCRIPTION The present invention relates to a new composition for use in the treatment of cough, comprising one or more polysaccharide fractions of plantain, one or more polysaccharide fractions of marshmallow, honey, brown sugar, one or more polyphenolic fractions of agrimony comprising tannins.
STATE OF THE PRIOR ART Classic pharmacological therapy is essentially based on cough suppression by chemical and pharmacological mechanisms. On the basis of their mechanism of action, anticough drugs can be classified into 3 categories: Mucolytics: increase mucus fluidity with mechanisms of depolymerization of mucoproteic complexes and of nucleic acids.
Expectorants: increase bronchial secretions and indirectly reduce mucus viscosity Sedatives: inhibit the cough centre, eliminating the symptom.
The limitations of anticough drugs lie in their specificity of action and in their side effects: mucolytics only act in moist cough; sedatives are indicated in dry cough only, hindering its physiological action; expectorants have a scarcely rational mechanism of action, so much so that in actual fact they are not prescribed.
Moreover, anticough drugs are scarcely adequate in pediatric age: in fact, mucolytics and central sedatives are contraindicated under age 2 years.
Therefore, a treatment of cough by non-irritating compositions, effective, stable and free from drugs such as, e.g., cortisone-based drugs or antibiotics, which can therefore be used without contraindications due to overdosage of such typologies of drugs and therefore also suitable for pediatric use, is of evident interest in the state of the art.
SUMMARY OF THE INVENTION A first aspect of the invention provides use of a composition comprising one or more polysaccharide fractions of plantain, one or more polysaccharide fractions of marshmallow, one or more polyphenolic fractions of agrimony comprising tannins, brown sugar, honey and one or more pharmaceutically acceptable carriers and/or excipients wherein said one or more polyphenolic fractions of agrimony comprising tannins comprises polyphenols at a percentage in weight greater than or equal to 3% in the manufacture of a medicament for the treatment of cough.
A second aspect of the invention provides a process for the preparation of a composition consisting of polysaccharide fraction/s of plantain, fraction/s polysaccharide of marshmallow, polyphenolic fraction/s comprising tannins of agrimony, brown sugar, honey and one or more of pharmaceutically acceptable carriers and excipients, wherein polysaccharide fraction/s of plantain, polysaccharide fraction/s of marshmallow, polyphenolic fraction/s of agrimony comprising tannins are mixed with honey, brown sugar and one or more pharmaceutically acceptable excipients and carriers wherein said one or more polyphenolic fractions of agrimony comprising tannins comprises polyphenols at a percentage in weight greater than or equal to 3%.
Therefore, the present invention relates to a formulation for the treatment of cough whose components are able to interact synergistically so as to intervene locally with mechanical-physical effects of its physio-pathogenetic mechanisms and having, jointly with a mucoadhesive effect of mucosal protection, also a powerful anti-oxidizing effect.
The formulation of the invention is able to act with a mainly mechanical effect: I. on inflammation (which is the factor triggering the cough), by an indirect action carried out through the formation of a protective layer which, on the one hand prevents further contact with external irritating agents and preserves mucous membrane hydration, and on the other hand, thanks to the intervention of anti- oxidizing substances, mitigates the noxious effect of the free radicals produced by infections; II. on mucus, making it more fluid and therefore more easily removable by physiological clearance mechanisms, by hydration thereof due to water-attracting hydrophilic substances.
Thus, the cough symptoms can be mitigated without nullifying its physiological role and promoting a restoration of normal conditions of mucus and mucous membrane.
The Authors of the present invention have made a composition having good mucoadhesive and barrier effect properties on the mucous membrane, jointly with anti-oxidizing properties comparable to those of vitamin C dosages commonly used in antitussive formulations stable over time, therefore not requiring the presence of the stabilizers commonly used for ascorbic acid stabilization.
The Authors have in fact made a composition in which a single ingredient, represented by agrimony (Agrimonia) is accountable both for the strong mucoadhesive properties of the formulation, and for its anti-oxidizing properties, such anti-oxidizing properties being comparable to those of vitamin C, but being much more stable than said vitamin.
In fact, it is known that the rapid degradation of ascorbic acid in aqueous products is to date a highly relevant factor in the formulation of products containing it. It is also known that ascorbic acid oxidation occurs rapidly in an alkaline environment.
Ascorbic acid degradation occurs both aerobically and anaerobically, and depends on many factors, such as oxygen, temperature, light, pH and storage conditions.
The composition subject-matter of the invention has instead shown excellent mucoadhesion and barrier effect abilities, anti-oxidizing activity comparable to that exerted by commonly used dosages of vitamin C, jointly with excellent stability over time. In fact, the composition of the invention, even in fluid form, proved stable when keeping the analyzed samples under extreme conditions, at 40°C and 75% of relative humidity. Obtained data are reported in the stability assay, in the Examples section.
As expected from the literature, and as also observed by the Inventors, vitamin C proved to be markedly unstable in the same fluid form (with the same excipients).
The present invention therefore provides a composition optimized for the treatment of cough, whose components as selected exhibit barrier effect, mucoadhesive and anti-oxidixing effect jointly with excellent stability over time.
Therefore, the present invention relates to a composition for use in the treatment of cough comprising one or more polysaccharide fractions of plantain, one or more polysaccharide fractions of marshmallow, one or more polyphenolic fractions of agrimony comprising tannins, brown sugar, honey.
The present invention also relates to a process for the preparation of said composition in one or more polysaccharide fractions of plantain, one or more polysaccharide fractions of marshmallow, one or more polyphenolic fractions of Agrimony comprising tannins are mixed with honey, brown sugar and one or more pharmaceutically acceptable carriers and/or excipients.
GLOSSARY For the purposes of the present invention, by "Plantain" it is meant Plantago lanceolata, by "Agrimony" Agrimonia eupatoria and by "Marshmallow" Althaea officinalis are meant.
By tops, or flowering tops, it is meant the term as commonly used in herbal medicine and in botanical treatises, therefore the aerial ends of the plant which contain leaves, stems (meant as branches and not as main stalk of the plant) and flowers, or at least one of these components.
By polysaccharide fractions of marshmallow and of plantain, there are meant fractions of extracts, preferably hydroalcoholic or aqueous ones, of marshmallow roots, and fractions of extracts, hydroalcoholic or aqueous ones, of plantain leaves, comprising polysaccharides.
By polyphenolic fractions of agrimony comprising tannins, there are meant fractions of extracts, preferably hydroalcoholic or aqueous ones, of tops or flowering tops of agrimony, comprising polyphenols, in particular comprising the polyphenolic subclass of tannins.
DETAILED DESCRIPTION OF THE FIGURES In figure 1, the mucoadhesivity percentage of the product under static conditions, at various dilutions, towards human buccal cells is reported, measured by assessment of the product ability to adhere to cells by inhibiting lectin binding with membrane glycoproteins, as illustrated in the detailed description and in the examples below.
Figure 1 shows such percentage for a formulation according to the invention in the form of syrup with the following dilutions: non-diluted, diluted 1:2 and diluted 1:5.
In figure 2, the resistance of the mucoadhesive layer under dynamic conditions is reported, i.e. assessing the product ability to remain adhered to the mucous membrane over time, by subjecting the system to a 2 ml/min flow of artificial saliva on a Franz cell as illustrated in the detailed description and in the examples below.
Figure 2 shows the resistance of the mucoadhesive layer obtained with the product in the form of syrup diluted 1:2 at different times, 0.5 h, 1 h and 2h towards a simulated salivary solution (0.9% NaCl physiological solution).
Figure 3 shows the assessment of the barrier effect exerted by the product in syrup, which forms a protective film able to protect cells from inflammatory agents (LPS) insult.
Figure 4 shows data obtained by performing the same steps of the Barrier assay carried out for figure 3, inverting however the stressing order of the cells, i.e. first stimulating the cells with LPS, and subsequently exposing them to the sample (invention composition and positive control), the data obtained show that the anti- inflammatory activity of the composition of the invention is to be attributed to a barrier effect and that it is not a direct anti-inflammatory activity.
Figures 5 and 6 show the results, expressed respectively as graph representing the development of free radicals over time, and histogram representing the scavenger action over time of various concentrations of the composition. The experiments were performed on 1 gram of the composition of the invention, brought to a final volume of 10 ml in saline and assayed at the maximum concentration of 0.5 mg/ml and at the minimum concentration of 0.03 mg/ml of composition.
Figure 7 shows a peculiar lectin labelling system, where the decrease in the absorbency value is proportional to the ability of the product to adhere ("mucoadhere") to cells.
DETAILED DESCRIPTION OF THE INVENTION Cough is a sudden expiratory manoeuvre that can occur as a reflex or as a voluntary action and has the aim of freeing the respiratory tract from any material present (expectorate), thereby performing a role indispensable to the physiological functioning of the respiratory system.
However, this system for defending the respiratory tract becomes a pathological condition when protracting in time, owing to repeated irritative stimuli (infective agents, irritating substances) causing excessive production of secretions and mucus, which accumulate in the respiratory tract and become a concomitant cause of tussive stimulus.
The mucous membrane lining the respiratory tract plays a protective role of functional barrier between the external environment and the tissues: a) represents a real physical barrier, protecting underlying tissues from contact with the outside; b) due to the presence of ciliated cells, with synchronized and unidirectional movements pushes mucus-entrapped foreign matter toward the esophagus; c) produces secretions and mucus; d) performs immunological functions, and in the presence of a virus enacts a series of effective defense mechanisms crucial in the antiviral response.
Part of its protective function is performed by the mucus covering it, which is an adhesive, viscoelastic gel produced by goblet cells and whose main macromolecules are glycoproteins.
It should be taken into account that the mucus, which under normal conditions has a protective role, in case of infection or other type of irritation becomes itself cause of cough: in fact, an overproduction and a higher viscosity thereof are witnessed.
The main mechanisms which onset from an infective and/or irritative event causing phlogosis of ear and throat can be described as follows: 1. direct involvement of larynx and trachea, due to their nearness and to the close communication relationships with mouth, pharynx and nose; 2. transport of inflammation mediators produced in the infection site, through the bloodstream, to the lower respiratory tract, where they initiate an inflammatory response; studies on guinea pigs and humans demonstrated that chemical-type sensory stimuli afferent from nose or esophagus can increase sensitivity to cough of the central nerve pathways, contributing to the "hypertussive" state accompanying inflammatory diseases of the respiratory tract, nose and esophagus. 3. in the post-nasal drip a continuous presence of mucus occurs, often in the form of viscous filaments difficult to expel from the nasopharynx, which by descending along the pharynx irritates it. This irritation causes a loss of coordination between nerves and muscles of trachea and esophagus, so that part of excess secretions pour into the larynx, causing a mechanical stimulation thereof which translates into a persistent, continuous and irritating cough, very frequent in children An important role in cough mechanisms is performed by the different types of receptors localized at the esophagus level, whose stimulation can trigger cough by various mechanisms: stimulation of tension mechanosensors by means of the repeated attempts at deglutition of the copious and viscous mucus in case of infective events; stimulation of mucosal receptors sensitive to light pressure stimuli exerted by mucous filaments stagnating between hypopharynx and esophagus; stimulation of nociceptors by inflammation mediators produced locally and carried by mucus to other sites (alike stimulation mechanisms have been demonstrated in guinea pig, even with acidic chemical stimuli) On the basis of the fact that both the physiological mechanisms for protection of respiratory tract mucous membranes and the pathogenetic processes of cough are actually based on mechanical-type mechanisms (mucus and intact mucous membrane on the one hand, mucus overproduction and mechanical stimulation on the other hand) the Inventors deemed that intervening with an action of mucous membrane protection could be the only approach really effective. The Inventors moreover sought and singled out a formulation, stable over time, based on substances of natural origins, that would have a high mucoadhesive ability, an effective barrier effect against irritating agents, jointly with a high anti-oxidizing action.
This required the development of a formulation that be active in its complexity, i.e. that its components be able to interact synergistically so as to intervene locally with mechanico-physical effects on its physio-pathogenetic mechanisms and concomitantly provide an anti-oxidizing effect enabling an effective protection from free radicals.
Bearing in mind such aim, a composition was made for use in the treatment of cough, comprising one or more polysaccharide fractions of plantain, one or more polysaccharide fractions of marshmallow, one or more polyphenolic fractions of agrimony comprising tannins, brown sugar and honey, along with one or more pharmaceutically acceptable carriers and/or excipients.
As indicated above, by polysaccharide fractions of plant x or y, or polyphenolic fractions of plant z comprising tannins, there are meant fractions of extracts of said plants, comprising the classes of compounds indicated and free from other classes of compounds commonly present in the parts of interest of the plant. In particular, the aforesaid fractions could be produced by hydroalcoholic extraction or aqueous extraction techniques. These fractions could be in form of hydroalcoholic or aqueous extracts, dry extracts, extracts dried by spray-drying technique (different from lyophilization), soft extracts or mixtures thereof.
The lyophilized extracts or the extracts dried by spray drying technique according to the invention can be lyophilized or dried hydroalcoholic or aqueous extracts.
According to the invention, the aforesaid fractions are preferably standardized for content of characteristic markers.
In one embodiment, the polysaccharide fraction of plantain is a fraction (or a set of fractions) comprising polysaccharides having a molecular weight higher than 20000 Daltons at a percentage in weight greater than or equal to 3%. E.g., 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%. According to a further embodiment, the polysaccharide fraction of marshmallow is a fraction (or a set of fractions) comprising polysaccharides having a molecular weight higher than 20000 Daltons at a percentage in weight greater than or equal to 5%. E.g., 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, %, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%.
According to one embodiment, the polysaccharide fraction of marshmallow is a mucilaginous fraction extracted from said plant.
According to still another embodiment, the polyphenolic fraction of agrimony is a polyphenolic fraction (or a set of fractions) (i.e., comprising polyphenols), comprising tannins, comprising polyphenols at a percentage in weight greater than or equal to 3%. E.g., 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, %, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%.
In one preferred embodiment, the composition comprises a polysaccharide fraction of plantain comprising polysaccharides with molecular weight higher than 20000 Daltons at a percentage in weight greater than or equal to 3%; a polysaccharide fraction of marshmallow is a fraction comprising polysaccharides with molecular weight higher than 20000 Daltons at a percentage in weight greater than or equal to %, and a polyphenolic fraction of agrimony comprising tannins, comprising polyphenols at a percentage in weight greater than or equal to 3%.
In the case of plantain and Marshmallow, lyophilized extracts or extracts dried by spray-drying are preferred, since for polysaccharide extraction solutions with a low percentage of alcohol or water are conventionally used, and such drying techniques are the best in order to give to the fractions the suitable characteristics for storage.
The preparation of such types of fractions can be carried out with well-known methodologies, therefore no further indication is needed for a technician in the field to carry out the present invention. However, in the Examples section there are reported suitable methods, not limiting the invention, for the preparation of fractions suitable for the composition of the invention.
The composition according to the invention is suitable for use in adult, geriatric-age, gestating, teenage and pediatric-age patients. The preparation of the extracts, as already mentioned, could be carried out according to any technique known to a person skilled in the art, in a specific embodiment, said extracts could be lyophilized extracts.
The honey could be bee honey, honeydew honey or a mixture thereof, and could be used it also in a lyophilized form or in any form.
The formulation could then comprise formulative agents such as thickening agents, flavourings, and preservatives (preservative agents) of natural or synthetic origin or other technological adjuvants that the technician skilled in the field could select according to the state of the art. By mere way of example, juices (such as lemon juice or other fruits flavours (e.g., natural orange flavour, natural lemon flavour, natural peach flavour, natural myrtle flavour, natural blackberry flavour), thickening agents (such as xanthan gum, gum arabic) could be selected.
Therefore, the above-described composition could consist in one or more polysaccharide fractions of plantain, one or more polysaccharide fractions of marshmallow, one or more polyphenolic fractions of agrimony comprising tannins, brown sugar, honey, and suitable excipients, flavours, preservatives.
In one preferred embodiment of the invention, the sole active principles comprised in the composition will be represented by one or more polysaccharide fractions of plantain, one or more polysaccharide fractions of marshmallow, one or more polyphenolic fractions of agrimony comprising tannins, brown sugar, honey.
Therefore, the composition of the invention can also be defined as a composition consisting of one or more polysaccharide fractions of plantain, one or more polysaccharide fractions of marshmallow, one or more polyphenolic fractions of agrimony comprising tannins, brown sugar, honey and pharmaceutically acceptable carriers and/or excipients.
According to one embodiment, the composition of the invention could comprise 30- 60% w/w of brown sugar; 20-50% w/w of honey; 0.1-2% w/w of polysaccharide fraction of plantain; 0.1-2% of polysaccharide fraction of marshmallow; 0.1-2% of polyphenolic fraction of agrimony comprising tannins and at least one of pharmaceutically acceptable carriers and/or excipients, q.s. to 100%.
Therefore, to weight percentages near to the upper end of the range of honey, there will correspond weight percentages near to the lower end of the range of brown sugar and vice versa, as the total sum of the parts in weight of the ingredients, including at least one pharmaceutically acceptable carrier and/or excipient is 100.
In the above-indicated ranges, the lower and upper ends, all values comprised between such ends, and all possible combinations of parts in weight of the ingredients falling within such intervals and whose sum be 100 are comprised.
Hereinafter, non-limiting examples of possible embodiments according to the invention are provided.
According to one embodiment, the composition of the invention could comprise 30- 50% w/w of brown sugar; 30-50% w/w of honey; 0.1-1% w/w of polysaccharide fraction of plantain; 0.1-1% of polysaccharide fraction of marshmallow; 0.4-2% polyphenolic fraction of agrimony comprising tannins, and at least one among pharmaceutically acceptable carriers and/or excipients, so as to have the overall amount reach 100% (that is, "q.s. to 100%").
According to another embodiment, the composition of the invention could comprise -55% w/w of brown sugar; 30-50% w/w of honey; 0.1-1% w/w of polysaccharide fraction of plantain; 0.1-5% polysaccharide fraction of marshmallow; 0.2-2% polyphenolic fraction of agrimony comprising tannins and at least one among pharmaceutically acceptable carriers and/or excipients, q.s. to 100%.
According to a further embodiment, the composition of the invention could comprise 40-60% w/w of brown sugar; 20-30% w/w of honey; 0.1-1% w/w of polysaccharide fraction of plantain; 0.1-5% polysaccharide fraction of marshmallow; 0.2-2% polyphenolic fraction of agrimony comprising tannins and at least one among pharmaceutically acceptable carriers and/or excipients, q.s. to 100%.
According to a still further embodiment, the composition of the invention could comprise 40-60% w/w of brown sugar; 20-30% w/w of honey; 0.1-1% w/w of polysaccharide fraction of plantain; 0.1-1.7% polysaccharide fraction of marshmallow; 0.2-1% polyphenolic fraction of agrimony comprising tannins and at least one among pharmaceutically acceptable carriers and/or excipients, q.s. to 100%.
According to yet another embodiment, the composition of the invention could comprise 40-60% w/w of brown sugar; 20-30% w/w of honey; 0.1-1% w/w of polysaccharide fraction of plantain; 0.1-1.6% polysaccharide fraction of marshmallow; 0.3-1% polyphenolic fraction of agrimony comprising tannins and at least one among pharmaceutically acceptable carriers and/or excipients, q.s. to 100%.
According to yet another embodiment, the composition of the invention could comprise 40-60% w/w of brown sugar; 20-30% w/w of honey; 0.2-1% w/w of polysaccharide fraction of plantain; 0.1-1.6% of polysaccharide fraction of marshmallow; 0.3-1% polyphenolic fraction of agrimony comprising tannins and at least one among pharmaceutically acceptable carriers and/or excipients, q.s. to 100%.
In all embodiments of the invention, the term "polysaccharide fraction" comprises also a set of fractions, as well as the term "polyphenolic fraction" also comprises a set of fractions, as long as the classes of above-indicated compounds are present, preferably in the concentrations indicated in the present description.
The compositions of the invention are therefore comprised of a set of functional substances having chemico-physical properties such as to perform overall a mucus-fluidifying effect and an effect of protecting the mucous membrane at the level of the application site represented by the upper respiratory tract.
As is apparent from the experiments reported in the present description, the composition according to the present invention has a percentage of mucoadhesion, when measured by assessment of the ability of the product, non-diluted or diluted to 1:5, to adhere to cells of the buccal mucous membrane in culture, inhibiting lectin binding with membrane proteins, of between 85 and 50%. Said ability is measured by treating cells of the buccal mucous membrane with the substance to be assayed (in this case with the composition of the invention) and then with biotinylated lectin, detecting with a suitable system (e.g. streptavidin peroxidase –o-phenylalanine) the lectin bound to said cells, comparing the amount of bound lectin in the sample treated with the composition of interest with respect to the amount of bound lectin in the control, in which cells are not treated with the composition of interest.
A scheme of the method used is reported hereinafter: The extent of mucoadhesion can be measured, e.g., by a colorimetric reaction enabling to quantify the sites on glycoproteins not engaged by the lectin, as engaged by the mucoadhesive product. The colorimetric reaction is possible thanks to a peculiar lectin labelling system, illustrated in Figure 7.
The decrease in the absorbency value is proportional to the ability of the product to adhere ("mucoadhere") to cells. The mucoadhesive ability is expressed as a percentage of inhibition of glycoprotein/lectin binding, and represents the percentage of mucosal sites occupied by the product according to the equation: Percentage of mucoadhesion of the product = (1 - abs sample/abs control) x 100 Where abs is for absorbency measured with a spectrophotometer at λ=450 The product is applied after dilution, taking into account the fact that in real use, right after delivery, a mixing with the saliva present in the oropharyngeal cavity occurs.
According to the present invention, the composition, non-diluted or diluted to 1:5 with a suitable diluent, could have a percentage of mucoadhesion, measured with lectin binding assay, of between 85% and 50%, preferably between 82 and 52% (see Figure 1).
With the expression of between 85% and 50% it is meant any integer, which could be 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50% and any decimal of the above- indicated integers lower than 85% and higher than 50% (therefore from 84.9% to 50.1%).
Any interval of mucoadhesive ability as measured above comprised between these two extremes is object of the invention.
Moreover, the composition of the invention has, as apparent from the assays carried out, a good resistance of the mucoadhesion to washing with saline, by subjecting the system to a 2 ml/min flow of artificial saliva on a Franz cell. This treatment, mimicking the resistance of the composition to saliva flow in situ, demonstrates that the composition of the invention is characterized by a high mucoadhesion lasting over time, as evident from the data reported in Figure 2.
Moreover, the composition can be further or alternatively characterized in that it exerts a protective barrier effect, assessed by calculating the percentage of reduction of the production of a cytokine in experiments conducted on cells in the presence of the product of the invention with respect to a positive Control without product, following contact with a suitable inflammatory agent able to induce the production of said cytokine.
As measuring system, any known inflammatory agent and a corresponding cytokine activated thereby can be used. An example of possible inflammatory agent system is represented by lipopolysaccharide (LPS) and IL-6.
The barrier effect assay is a biological-type in vitro assay employed for assessing the ability of finished products and/or raw materials to protect, through the formation of a thin "insulating" layer, mucous membranes and skin from contact with environmental contaminants (dust, pollens, microorganisms, etc.) The assay was developed to simulate in vitro the action exerted by products that are applied on skin and/or mucous membranes with the aim of creating a protective film against external aggressors.
The model takes advantage of the principle whereby cells subjected to contact with an inflammatory agent produce and secrete pro-inflammatory mediators (cytokines) in the extracellular environment in an amount related to the degree of inflammation caused; within a certain range, a direct proportionality exists between concentration and times of exposure to the inflammatory agent and amounts of cytokines released.
The experimental model adopted provides two chambers physically separated by a semi-permeable membrane (0.4µm pores). Cells are seeded in the lower chamber, whereas the upper chamber accommodates the inflammatory agent; on the semi-permeable membrane separating the two chambers a thin film of the sample under analysis is stratified to highlight, if present, a barrier effect to the free transit of the inflammatory agent.
The semi-permeable membrane allows passage of the inflammatory agent in the lower chamber and constitutes the support on which the sample to be assayed is stratified. Depending on the "insulating" ability of the sample, a decrease of LPS migration from the upper chamber to the bottom one will be had (therefore a lesser stimulation of cells to cytokine production).
The assays carried out showed that the barrier effect exerted by the composition of the invention reduces IL-6 marker production, in cells subjected to the action of an inflammatory agent in the presence of said composition, of about the 65-75%, with respect to control cells subjected to the action of the same inflammatory agent in the absence of said composition.
This assay was developed in order to simulate in vitro the protective action of substances and formulations that, applied on skin and mucous membranes, form an "isolating" film towards external agents. The model takes advantage of the principle whereby cells subjected to contact with an inflammatory agent produce and secrete pro-inflammatory mediators (cytokines) in the extracellular environment in an amount related to the degree of inflammation caused. The assay envisages the setting up of two chambers physically separated by a semi-permeable membrane allowing transit of sufficiently small solutes.
In the lower chamber, consisting of a well containing plates for cell cultures, cells are grown (primary cell line of human fibroblasts - HUDE), whereas the upper chamber consists of the insert (transwell) and accommodates the inflammatory agent LPS.
On the internal surface of the transwell membrane separating the two chambers, a thin film of the sample being examined is stratified to assess any barrier effect (BE) upon free transit of the inflammatory agent.
The extent of the inflammatory reaction is assessed through semiquantitative dosage of the cytokines released in the culture medium of the lower chamber, in particular of interleukin 6 (IL-6) typical of the late phase of the inflammatory reaction.
In the Table below, the results obtained with the above-described experiment, summed up in Figure 3 are reported.
SAMPLE IL-6 (pg/µL) AVERAGE S.D.
Composition according to Table 4 + LPS 325.53 Composition according to Table 4 + LPS 332.97 10.00 344.33 Composition according to Table 4 + LPS 329.05 Control + 1 (LPS) 1274.47 Control + 2 (LPS) 1145.56 150.73 979.83 Control + 3 (LPS) 1182.39 Control - 1 (MEM) 72.03 Control - 2 (MEM) 54.40 63.28 8.82 Control - 3 (MEM) 63.41 From the results, it is apparent a remarkable reduction in concentration of IL-6 produced in experiments in which the assayed product is present.
The IL-6 value equal to 63.28 pg/µL detected for the Negative Control is comparable to a normal basal value, i.e. a non-inflammatory condition.
The next graph clearly shows the protection exerted by the products on the cells.
Data are expressed in terms of Fold Over (F.O.) compared to the Control C- by applying the following formula: FOLD OVER (C-) = [measured IL-6]/[C-IL-6] From the mean IL-6 values measured in the barrier assay and in the positive control, the percentage of IL-6 release reduction is calculated: 100-[(IL-6SAMPLE)/ IL-6C+) X 100] Therefore, by applying the formula it is obtained a value of reduction of IL-6 production, in the experiments conducted in the presence of the assayed samples.
The mean value obtained by performing the assay with the composition of the invention was of 70.93 % compared to the positive control as reported in Figure 3.
In order to verify to verify that the results depend on the sole barrier effect of the assayed samples and exclude any interferences with cytokine synthesis (anti- inflammatory effect), concomitantly to the barrier assay (B.A.) on each sample also an INTERNAL CONTROL (IC) assay was performed, in which the same steps of the above-described barrier assay were performed, inverting however the stressing order of the cells: cells were first stimulated with LPS and subsequently exposed to the sample.
In this case, interleukin production is not affected by the presence of the samples, as shown by the graph reported in Figure 4, indicating that the products do not possess direct anti-inflammatory activity. Lastly, the cell viability assay indicates that none of the operations carried out and of the treatments performed proved cytotoxic for the cells.
The results obtained, not reported, show a good ability by the tablets to form a protective barrier hindering the transit of the inflammatory agent LPS.
The authors of the invention have carried out experiments for assessing the anti- oxidizing activity of the composition of the invention at various dilutions by an experiment carried out in parallel on the composition of the invention with respect to a blank and with respect to vitamin C solubilized in said blank.
Therefore, the data reported hereinafter show how the composition of the invention also has an excellent anti-oxidizing activity, and how said composition remains stable also in fluid form with respect to the vitamin C suspended in the same excipients.
The data obtained showed that the composition of the invention has a free radical scavenger action comparable to that exerted by vitamin C when introduced in replacement of the polyphenolic fraction of agrimony in the composition of the invention. Figures 5 and 6 show he results, expressed respectively as graph representing the development of free radicals over time and histogram representing the scavenger action over time of various concentrations of the composition. The experiments were performed on 1 gram of the composition of the invention, brought to a final volume of 10 ml in saline and assayed at the maximum concentration of 0.5 mg/ml and at the minimum concentration of 0.03 mg/ml of composition.
The experiment was carried out by assessing the effectiveness of the sample analyzed to neutralize the free radicals generated by treating cultured cells with a 500µM H O solution. The protection from H O -induced oxidative stress was 2 2 2 2 expressed in terms of percentage of protection from development of free radicals measured with the assay reported in experimental example 2, at a time of 100 minutes.
In the experimental section there are reported in detail the experiments carried out for the assessment of the scavenger activity of the composition of the invention.
The experiments carried out showed that the composition of the invention has good scavenger action, able to neutralize H O -induced free radicals (FR): the first dose analyzed (0.5 mg/ml) reduces FR formation of the 395355 and 56%, respectively, after each exposure time; the second dose analyzed (0.25 mg/ml) reduces FR formation of the 40 – 50 – 51 – 49 – 48 and 47%, respectively, after each exposure time; the third dose (0.125 mg/ml) reduces FR formation of the 41 – 43 – 42 – 35 – 32 and 30%, respectively after each exposure time; the fourth dose (0.0625 mg/ml) reduces FR formation of the 31 – 32 – 30 –27 – 25 and 23%, respectively, after each exposure time, and the fifth dose (0.0313 mg/ml) significantly inhibits FR formation of the 30– 26 – 24 – 23 – 22 and 19%, respectively, after each exposure time.
Ascorbic acid (0.05 mg/ml) has a scavenger action able to reduce FRs of the 45 – 57 – 60 – 60 – 63 e 61% respectively after the six times of exposure to the stress, therefore with values comparable to those of the first dose of composition examined.
According to the present invention, the composition can be made for oral administration and could be made in the form of tablet, pill, granules, powder, syrup, fluid, elixir, spray, suspension, emulsion, solution.
For oral administration the composition could be made in the form of daily unit dosages or of fractions of daily unit dosages (e.g., 2, 3, 4, 5, 6, or more tablets, pills, granule or powder single-doses, syrup, elixir, spray or fluid could be taken over the day, in accordance with the judgment of the treating doctor), and may contain conventional excipients including, e.g., binding agents, thickening agents, like gums (gum tragacanth, gum arabic), animal gelatine and polyvinylpyrrolidone; diluents, such as sugar, polyalcohols (sorbitol, mannitol, xylitol), maltodextrins, inorganic salts (bibasic calcium phosphate, calcium carbonate); disintegrants, like rice starch, corn starch and potato starch; lubricants, like magnesium stearate, polyethylene glycols with different molecular weights; glidants, like colloidal silica; antiadhering agents, such as, e.g., talc; wetting agents like sodium lauryl sulfate. The tablets may be coated according to methods well-known in standard pharmaceutical practice.
The composition could also be made in a liquid or semi-liquid form, as a suspension, emulsion, solution for oral administration, and could optionally contain natural flavourings giving a palatable taste thereto.
The composition in the form of powder or granule could be pre-metered in suitable containers and ready for use, either by ingestion as such or to be resuspended in an appropriate liquid such as water, tea, etc. In this case as well, the composition could contain natural flavourings giving a palatable taste thereto.
Evidently, all of the above-indicated excipients could be used in a pharmaceutically acceptable grade.
In one embodiment, the composition as described herein, in any one of the above-indicated embodiments, could be in the form of pharmaceutical composition, i.e. comprise pharmaceutical-grade ingredients, or it could be or be introduced into a medical food or into a medical device.
The composition according to the present description could be made in the form of pharmaceutical composition or of medical device according to any one of classes described in Directive 93/42/EEC on medical devices (comprising also substances and not only "devices" in the sense of objects).
In case of a syrup there could be used, besides the above-described active components and one or more of the previously described agents (preservatives, thickening agents, excipients, flavouring, etc.).
Therefore, in a specific embodiment of the present invention, the composition could be consisting of or comprise the following components: Table 3 BROWN SUGAR HONEY EXCIPIENTS AND/OR CARRIERS Polysaccharide fraction of marshmallow (e.g., lyophilized or spray-dried extract) Polysaccharide fraction of plantain (e.g., lyophilized or spray dried extract) Polyphenolic fraction of agrimony (e.g., lyophilized or spray-dried extract) Optional CARRIERS, NATURAL FLAVOURINGS, EXCIPIENTS could be, e.g., in the following proportions: Table 4 General composition %w/w BROWN SUGAR 40-60 HONEY 20-30 WATER CARRIER 10-40 Polysaccharide fraction of plantain LEAVES 0.1-1 0.1-1 Polysaccharide fraction of MARSHMALLOW Polyphenolic fraction of AGRIMONY 0.1-1 The present invention also relates to a process for the preparation of said composition, wherein extracts of plantain, of marshmallow and of agrimony as described above are mixed with honey, brown sugar and one or more natural flavourings, preservatives, thickening agents and optionally with pharmaceutically acceptable excipients.
Lastly, the present invention also relates to a method for the treatment of dry cough, productive cough, URTI (upper respiratory tract infections)-associated cough and cough from post-nasal drip comprising the administration of a therapeutically active dosage of the composition of the invention to a patient in need thereof, wherein said patient can also be in pediatric age, geriatric age, gestating.
FORMULATION EXAMPLES Hereinafter, some specific examples of liquid formulation are provided which are not to be understood as a limitation of the application.
Table 5 COMPOSITION EXAMPLE 1 %w/w BROWN SUGAR 30-50 HONEY 30-50 DEIONIZED WATER and/or other suitable carrier or excipient 40-60 0.1-1 Polysaccharide fraction of plantain 0.1-1 Polysaccharide fraction of marshmallow Polyphenolic fraction of agrimony 0.4-2 Table 6 COMPOSITION EXAMPLE 2 %w/w BROWN SUGAR 35-55 HONEY 30-50 SORBITOL SYRUP 40-60 Polysaccharide fraction of plantain LEAVES 0.1-1 0.1-1.5 Polysaccharide fraction of marshmallow Polyphenolic fraction of AGRIMONY 0.2-2 Table 6 COMPOSITION EXAMPLE 3 %w/w BROWN SUGAR 40-60 HONEY 20-30 MANNITOL SYRUP excipient 10-40 Polysaccharide fraction of plantain LEAVES 0.1-1 0.1-1.5 Polysaccharide fraction of MARSHMALLOW Polyphenolic fraction of AGRIMONY 0.2-2 Table 7 COMPOSITION EXAMPLE 4 %w/w BROWN SUGAR 40-60 HONEY 20-30 XYLITOL SYRUP excipient 10-40 Polysaccharide fraction of plantain LEAVES 0.1-1 0.1-1.7 Polysaccharide fraction of MARSHMALLOW Polyphenolic fraction of AGRIMONY 0.2-1 Table 8 %w/w COMPOSITION EXAMPLE 5 BROWN SUGAR 40-60 HONEY 20-30 XYLITOL SYRUP excipient 10-20 MANNITOL SYRUP 10-20 Polysaccharide fraction of plantain LEAVES 0.1-1 0.1-1.6 Polysaccharide fraction of MARSHMALLOW Polyphenolic fraction of AGRIMONY 0,3-1 Table 9 %w/w COMPOSITION EXAMPLE 6 BROWN SUGAR 40-60 HONEY 20-30 DEIONIZED WATER and/or other suitable carrier or excipient 10-20 GLUCOSE SYRUP 10-20 MALTITOL SYRUP 10-20 0.2-1 Polysaccharide fraction of PLANTAIN 0.1-1.6 Polysaccharide fraction of MARSHMALLOW Polyphenolic fraction of AGRIMONY 0.3-1 In one preferred embodiment, in all of the above-reported examples the polysaccharide and polyphenolic fractions are lyophilized or dried by spray drying.
EXPERIMENTAL EXAMPLES The following experimental examples have the purpose of illustrating some of the assays performed on the composition of the present invention. 1. MUCOADHESION ASSAY The mucoadhesive effect of a product, contributing to the formation of the protective film on the mucous membranes, can be assessed by suitable in vitro models.
The model used demonstrates that the mucoadhesivity of products intended for the treatment of the mucous membranes can be determined by assessment of percentage of lectin-glycoprotein binding inhibition. Mucosal buccal cells are initially treated with biotinylated lectin (Con-A), a protein contained in some Leguminosae (Canavalia ensiformis) having a high affinity for the glucoside and mannoside residues present in the glycoproteins of the membrane. The sites of the glycoproteins of the mucous membranes will thus be all engaged with the biotinylated lectin (treated with biotin, i.e. vitamin H). The cells, treated with biotinylated lectin, are charged with streptavidin peroxidase, making it possible to form the protein/glucose/lectin/biotin/streptavidin peroxidase complex thanks to the high affinity between biotin and streptavidin.
At this point, the cells are washed, and the protein/glucose/lectin/biotin/streptavidin peroxidase complex is quantified, assessing peroxidase activity, by means of a reaction of oxidation of the ortho-phenylenediamine (colorimetric assessment).
In fact, the protein/glucose/lectin/biotin/streptavidin peroxidase complex will catalyze the oxidation reaction: O-phenylenediamine 2,3-diaminophenazine (yellow) Strep.perox.
The intensity of the yellow/orange coloration of the solution (measured using a spectrophotometer with λ=450 nm) is proportional to the quantity of glycoprotein- lectin bonds and therefore to the quantity of available sites (glycoproteins) for mucoadhesion The absorbency value thus determined constitutes the "control".
When determining the mucoadhesivity of a product, the cells are treated preliminarily with this product (incubation at 30°C for 15 minutes before the treatment with lectin).
If the product under examination contains mucoadhesive substances, these will bind to the glucoside and mannoside sites present in the membrane glycoproteins.
In the next phase, adding the sequence of biotinylated lectin, streptavidin peroxidase and ortho-phenylenediamine there will be obtained a less intense colouration, compared to the control, and this since part of the glucoside sites available for binding with the Con-A were already occupied by the mucoadhesive substances present in the product to be assayed. In fact, the initial binding between the mucoadhesive substances contained in the product to be assayed, and the glucoside sites partly compromises the subsequent conjugation of the Con-A with the streptavidin peroxidase complex and the consequent development of colour after addition of oxygenated water.
The decrease in the absorbency value is proportional to the ability of the substances under examination to "mucoadhere" to mucosal cells.
The mucoadhesive ability is expressed as a percentage of inhibition of glycoprotein/lectin binding, and represents the percentage of mucosal sites occupied by the product according to the expression: Percentage of mucoadhesion of the product = (1 – abs sample/abs control) x 100 Furthermore, in addition to the mucoadhesive ability, it is also assessed the resistance of the mucoadhesive layer to the action of the salivary solution with which it comes to contact.
To this end, in a second phase of the experiment, the resistance over time (0.5-2h) of the mucoadhesivity of the product after exposure to a continuous flow of artificial salivary solution.
To perform this assay, a system of Franz cells, generally being used in the assessment of percutaneous absorption of a substance or for the study of other processes of permeation through natural or artificial membranes.
In the experiment, the buccal cellular cultures were deposed in the donor and were treated with formulations of the product as described in the assay at 2, at different dilutions, as reported in figure 2, (a dilution in all likelihood nearer to the real conditions that might occur in vivo). The donor was then fed with a continuous flow (2 ml/min.) of artificial salivary solution, by a peristaltic pump.
At the base of the donor, in the zone of separation with the receptor, a cellulose acetate membrane was placed, capable of allowing outflow of the salivary solution from the donor to the receptor, retaining the mucosal cells in the donor.
The salivary flow through the mucosal cells treated with the product under examination was regularly discontinued after 0.5, 1, 2 hours and the cells of the donor transferred into a suitable test tube for mucoadhesivity assessment.
In light of the results obtained, it is possible to state that the product, demostrating to possess good, resistant mucoadhesivity, can play an interesting protective role on mucosal cells of the oral tract.
In order to mimic the natural dilution of a syrup in the oral cavity, the mucoadhesivity assays were carried out on a product diluted 1:2; for greater completeness, also the mucoadhesivity of the product diluted 1:5 was assayed.
The mucoadhesivity percentage of the non-diluted, or diluted (1:2 and 1:5) product towards human buccal cells is reported in Figure 1.
The resistance of the mucoadhesive layer obtained with the product diluted 1:2 at different times, 0.5 h, 1 h and 2h towards a simulated salivary solution (0.9% NaCl physiological solution) is shown in Figure 2. 2. SCAVENGER-TYPE ANTI-OXIDIZING ACTIVITY ASSAY Assessment of anti-oxidizing activity of the sample on human cells exposed to chemical-type progressive oxidative stress.
The assessment of anti-oxidizing action is obtained from quantification of free radical formation in cells exposed to the sample and to oxidative stress.
The method applied is based on the use of the fluorimetric probe 2,7 dichlorofluorescein acetate –DCA-: this probe penetrates into cells, binds to cell membrane proteins and macromolecules. In this form, the probe is not fluorescent, only becoming fluorescent when oxidized by free radicals. Cells pretreated with DCA are exposed to the various dilutions of the sample and hydrogen peroxide. At regular intervals of 20 minutes to 100 minutes (5 measurements), free radical formation is assessed with a fluorimeter (Victor X4 Perkin Elmer): the scavenger action is obtained by a comparison of free radicals produced by cells exposed to the sample and to hydrogen peroxide and those exposed to the sole hydrogen peroxide.
Compositions according to examples 2, 4 and 6 were prepared. 1 g of composition consisting of 0.2% w/w of polysaccharide fraction of marshmallow, 0.35% of polysaccharide fraction of plantain, 0.2% of polyphenolic fraction of Agrimony comprising tannins, 25% of honey (for compositions 4 and 6, and 35% for composition 2), 46.6% of brown sugar and pharmaceutically acceptable carriers and excipients (according to the respective examples) was weighed and brought to a final volume of 10 ml (10 mg/ml) in saline. The assayed solution had a pH greater than 7. Starting from this mother solution, the first dilution was prepared at a concentration of 0.5 mg/ml in saline; therefrom, by applying a 1:2 dilution factor, the other four dilutions were obtained.
Other compositions according to the composition examples above were also assayed, giving analogous results. The absence of anti-oxidizing activity of the carriers and excipients used in the compositions was also verified. Concomitantly with the composition, also a positive control and an internal control were analyzed.
Positive Control: cells exposed to the 500μM H O solution.
Internal Control: cells exposed to an ascorbic acid solution (0.05 mg/ml).
Negative Control: cells exposed to the inoculation medium.
The assay was performed on a simple cell model consisting of a monolayer of stabilized human keratocytes (cells were purchased from IZSLER and are guaranteed as free from any viral/bacterial contamination and/or from mycoplasma).
Description of reagents/solutions and related abbreviations: Fetal Calf Serum FCS Sodium Dodecyl Sulfate SDS Culture medium: Dulbecco High Glucose (D-MEM) completed with glutamine (2mM), antibiotics such as penicillin (2000 UI/ml)-streptomycin (1000 UI/ml)- Fungizone (2μg/ml) and Fetal Calf Serum (10%), hydrocortisone 0.5ng/ml, Insulin 5μg/ml, Epithelial Growth Factor 0.01μg/ml DMEM Inoculation medium: Dulbecco High Glucose (D-MEM) completed with glutamine (2mM), antibiotics such as penicillin (2000 UI/ml)- streptomycin (1000 UI/ml)- Fungizone (2μg/ml) and Fetal Calf Serum (5%), hydrocortisone 0.5ng/ml, Insulin 5μg/ml, Epithelial Growth Factor 0.01μg/ml DMEMi Phosphate buffer PBS Neutral Red working solution: 0.4% stock solution is diluted in Minimum Essential Medium (MEM), filtered on paper immediately before use. Use concentration is 0.04% NRw Neutral red extraction fluid: prepared some minutes before use, consisting of 49% distilled water - 50% Ethanol – 1% glacial acetic acid ExB 2,7 DICHLOROFLUORESCEIN DIACETATE: 4μm DCA Dosages, administration route and analytical replicates Two series (in the presence and absence of H O ) of five base 2 dilutions of the sample: of 0.5 – 0.25 – 0.125 – 0.0625 and 0.0313 mg/ml, were set up. The same procedure was carried out to obtain the same five dilutions in a 500µM H O solution in saline. 150μl per each dilution (in saline and in H2O2) were distributed into four wells on two different plates.
Day 1 Cell seeding Cultured cells were enzymatically detached from the growth medium and counted with an electronic cell counter (Scepter); a cell suspension was prepared (in inoculation medium) at the density of 300,000 cells/ml, which were then distributed into 96-well plates: 100μl per well, obtaining a seeding density of 30,000 cells per well. Lastly, the plates were placed back to culture in an incubator at 37°C and 5% CO -enriched humid atmosphere for the subsequent 24 hours.
Day 2 Exposure to DCA probe The inoculation medium was removed, cells were washed once with PBS, then PBS was discarded and 150μl DCA (4μM) was distributed in both plates. Then, the plates were placed back in incubator at 37°C and 5% CO -enriched atmosphere for minutes.
At the end of the DCA incubation period, the solution was removed, and cells were washed once with PBS, then 150μl of the above-described dilutions of the sample and of the controls were distributed in the plates. Then, free radical formation was measured from T0 (right after inoculation into the two plates) every 20 minutes, up to 100 minutes (5 measurements) with a fluorimeter. At the end of the measurements, after the 100 minutes, the inoculate of both plates was removed and Neutral Red Uptake vitality assay was performed.
The cells were left contacting 150μl of NRw for 3 hours at 37°C in an incubator with % CO -enriched atmosphere. Neutral red (NR) penetrates the cells and is stored in lysosomes. Only vital cells that have kept membrane functionality intact will be able to retain NR. Accordingly, the greater the number of vital cells, the greater the amount of NR stored in the cells. At the end of the three hours of incubation, plates were collected, the NR solution was removed, and cells were subjected to washings with 150μl of PBS to eliminate NR in excess. Then, extraction of Neutral Red accumulated in lysosomes was carried out by applying, in each well, 150μl of ExB.
The extraction stage was protracted for 15 minutes under stirring at room temperature. Thus, a red fluid is obtained whose intensity, proportional to the number of vital cells present, is measured by spectrophotometric reading at 570±30 The intensity of emitted fluorescence and of Neutral Red extracted in 96-well plates was measured by fluorimetric and spectrophotometric reading at 540 nm with a Victor X4 (Perkin Elmer) plate reader.
RESULT ASSESSMENT AND CALCULATION Survival rate detection %Vitality=[(O.D. Sample ± H O / O.D. ControlPos/Neg)x100] % Vitality inhibition=(100-% Vitality) O.D.: optical density O.D. Sample ± H O : optical density average, obtained from cells exposed to the sample with and without H O O.D. positive/Negative control: optical density media obtained from cells exposed to the H O solution or to the sole saline (100% Vitality) Assessment of scavenger anti-oxidizing activity F.U.: fluorescence unit F.U. positive control: average of F.U. emitted from cells exposed to the H O solution (maximum production of free radicals) F.U. negative control: average of F.U. emitted from cells not exposed to oxidative stress At each time interval of exposure (T0-T1-T2-T3-T4-T5) there were carried out: 1) Normalization the average of F.U. emitted from cells exposed to the sample, to vitamin C without oxidative stress, is subtracted from the average of F.U. emitted from cells exposed to the sample, to vitamin C and oxidative stress. In other words, the average values of fluorescence emitted from the non-stressed plate were subtracted from the average values of fluorescence emitted from the stressed plate. 2) Calculation of the percentage of free radical abatement: % FR inhibition = [100-(F.U. Sample -F.U. Sample ) / (U.F.Control - U.F.Control )*100] pos neg pos neg F.U. Sample : cells exposed to the sample and to oxidative stress F.U. Sample : cells exposed to the sole sample F.U. Control : cells exposed to the sole oxidative stress F.U. Control : cells exposed to saline without oxidative stress Study acceptance criteria Sample- Positive and negative control: variation coefficient must be <20%.
Variation coefficient VC= ((sd/OD )x100) average p value (type 2 two-tailed t test) must be lower than 0.05%.
The Table below reports data related to free radical development. The data are reported, processed, in Figure 5.
Table 10 Composition of the invention mg/ml FREE RADICAL DEVELOPMENT 0.5 mg/ml 0.25 mg/ml 0.125 mg/ml 0.063 mg/ml 0.03 mg/ml Vit. C 0.05mg/ml Neg.Cntrl T0 6311.67 6178 6072 7070 7237 5654 10315 MIN 7026 6984 7993 9473 10308 5993 14015 40 MIN 6643 6945 8228 10021 10758 5721 14248 60 MIN 6192 6716 8543 9582 10140 5240 13120 80 MIN 5952 6813 8861 9797 10173 4802 12789 100 MIN 5534 6643 8857 9649 10181 4937 12600 The data reported in the table show that, at 0.5 mg/ml and 0.25 mg/ml dilutions, the values obtained with the composition of the invention are comparable to those obtained with vitamin C.
The obtained data were then processed in terms of % of protection from free radicals exerted by analyzed substances.
The Table below reports data related to the results obtained. What reported in the table below was graphically processed in Figure 6.
Table 11 Composition of the invention mg/ml % PROTECTION FROM FREE RADICALS 0.5 mg/ml 0.25 mg/ml 0.125 mg/ml 0.063 mg/ml 0.03 mg/ml Vit. C 0.05mg/ml T0 39 40 41 31 30 45 MIN 50 50 43 32 26 57 40 MIN 53 51 42 30 24 60 60 MIN 53 49 35 27 23 60 80 MIN 55 48 32 25 22 63 100 MIN 56 47 30 23 19 61 The data reported in the table show that, at 0.5 mg/ml and 0.25 mg/ml dilutions, the values obtained with the composition of the invention are comparable to those obtained with vitamin C.
The table below reports the statistical significance of obtained results.
Table 12 Composition of the invention mg/ml STATISTICAL SIGNIFICANCE (p Value) 0.5 mg/ml 0.25 mg/ml 0.125 mg/ml 0.063 mg/ml 0.03 mg/ml Vit. C 0.05mg/ml T0 9.26E-11 1.72E-10 8.79E-11 8.61E-09 5.25E-09 7.10E-11 min 1.92E-09 3.38E-09 3.04E-08 1.05E-06 4.93E-06 6.88E-10 40 min 6.56E-10 1.41E-09 1.57E-08 1.27E-06 8.58E-06 2.04E-10 60 min 3.23E-09 2.14E-08 4.76E-07 1.54E-05 7.96E-05 8.91E-10 80 min 1.44E-06 6.42E-06 3.54E-04 3.12E-03 8.32E-03 2.62E-07 100 min 4.43E-07 3.20E-06 3.22E-04 2.42E-03 8.19E-03 1.71E-07 As is apparent from the above Table, statistical analysis of obtained results confirmed that the test carried out fulfills all required acceptability criteria, therefore validating the data generated for examined substances.
Summing up the foregoing, the assays performed on samples of the composition of the invention in various embodiments as described above demonstrated that the composition has a good scavenger action, able to neutralize H O -induced free radicals (FR): the first dose analyzed (0.5 mg/ml) reduces FR formation of the 39- 5053-55 and 56%, respectively, after each exposure time. By virtue of this result, this dose may be deemed the most effective dose.
The second dose analyzed (0.25 mg/ml) reduces FR formation of the 40 – 50 –51 – 49 – 48 and 47%, respectively, after each exposure time.
At the third dose (0.125 mg/ml), FR formation is reduced of the 41 – 43 – 42 – 35 – 32 and 30%, respectively, after each exposure time.
At the fourth dose (0.0625 mg/ml) FR formation is reduced of the 31 – 32 – 30 –27 – 25 and 23%, respectively, after each exposure time.
The fifth dose (0.0313 mg/ml) significantly inhibits FR formation of the 30– 26 – 24 – 23 – 22 and 19%, respectively, after each exposure time.
Ascorbic acid (0.05 mg/ml) has a scavenger action able to reduce FRs of the 45 – 57 – 60 – 60 – 63 and 61%, respectively, after the six times of exposure to stress.
Neutral Red Uptake vitality assay, performed on the plate not exposed to oxidative stress, highlighted no reduction of cell vitality such as to compromise the significance of the assay.
Accordingly, the composition of the invention, taking into account the high force of the stress applied, proved to be a good scavenging agent. 3. ASSESSMENT OF STABILITY OF THE COMPOSITION OF THE INVENTION The stability of the composition of the invention in fluid form (syrup, as per examples above, at 2) with regard to tannins was assessed by measuring the content of total tannins, expressed as pyrogallol, by means of spectrophotometric method described in European Pharmacopoeia (EP 9.2, 2.8.14) for agrimony.
As can be observed from data reported in the Table below, no changes in titer are observed in the space of six months, keeping the sample under extreme conditions, at 40°C and 75% of relative humidity.
Vitamin C, in preparations that differed in formulation solely due to the presence of vitamin C in lieu of the tannins, did not exhibit stability beyond T0.
Tannins such as Pyrogallol Check point T0 T3 months T6 months Accelerated stability (40°C, RH 75%) 0.05 0.05 0.05 4. BARRIER EFFECT ASSAY For the barrier effect assay, two chambers physically separated by a semi- permeable membrane (0.4µm pores) were used. Human fibroblast cells were seeded in the lower chamber, whereas the inflammatory agent LPS (purified E. Coli lipopolysaccharide) was introduced into the upper chamber; on the semi-permeable membrane separating the two chambers a thin film of the composition as described in the present invention was stratified.
Induced inflammatory response was estimated through semi-quantitative dosage of Interleukin 6 (IL6) cytokine released in the culture medium of the lower chamber: barrier effect assessment was obtained by comparison with the positive control in which the two chambers were separated by the same type of semi- permeable membrane, free however from any barrier.
As to the threshold value above which it may be said that a substance causes a barrier effect in the assay reported herein, a value equal to 15% of inhibition as compared to the control was identified by the Inventors, during the setting up of the assay, on the basis of assays carried out on substances known to have a barrier effect.
Then, the barrier effect of the composition in the formulations at 2. above was evaluated.
The data reported in Figure 3 show how the composition has a remarkable barrier effect.
The assessment assay was carried out as follows, through a method developed to simulate in vitro the protective action of substances and formulations which, when applied to the skin and mucous membranes in vivo, form an "insulating" film against environmental agents.
The model takes advantage of the principle whereby cells subjected to contact with an inflammatory agent produce and secrete pro-inflammatory mediators (cytokines) in the extracellular environment in an amount related to the degree of inflammation caused. The greater the amount of inflammatory agent reaching the cells, the greater the amount of cytokines released.
Two chambers were set up, physically separated by a semi-permeable membrane which allows the transit of sufficiently small-sized solutes.
In the lower chamber, consisting of a well containing plates for cell cultures, HuDe cells (no. BS PRC 41, purchased from the Istituto Zooprofilattico di Brescia, Italy) are grown, while the upper chamber, consisting of an insert for complex cell cultures (transwells) accommodates the inflammatory agent.
On the surface of the semi-permeable membrane of the insert separating the two chambers On the surface of the semi-permeable membrane of the insert separating the two chambers, before the introduction of the inflammatory agent in the upper chamber, a thin film of the sample being examined is stratified to assess any BE upon the free transit of the inflammatory agent.
Depending on the insulating capabilities of the sample, there will be had a decrease of the migration of the inflammatory agent from the upper chamber and, as a consequence, a lesser stimulation of the cells to produce cytokines. The extent of the inflammatory reaction is estimated through the semi-quantitative dosage of cytokines released in the culture medium of the lower chamber, in particular of interleukin 6 (IL-6).
As a control a similar experiment is used in which no sample is stratified on the membrane, thus making it possible to measure the effect of the inflammatory agent without any barrier in addition to the semi-permeable membrane.
Moreover, an internal control is used in which the cultured cells are pre- treated with the substance adapted to induce marker release and the sample is placed on the semi-permeable membrane in the absence of said substance, one or more measurements in time are thus performed of the quantity of marker in the culture medium of said internal control. In the internal control, the cells are therefore stimulated first with the inducing substance and then there has to be assessed whether the sample which may pass the membrane and go into the cells pushed by the medium above has any effect in decreasing the release of the marker not related to the barrier effect. For instance, when an inflammatory agent is used as the inducing substance, the internal control makes it possible to understand if the reduction in the concentration of cytokines in the culture medium is due to the barrier effect or if the sample that may pass into the cells pushed by the medium above has any effect in reducing the inflammatory response independently of the barrier effect.
The barrier effect (BE) is expressed as a percentage of the reduction of the release of IL-6 and is calculated through comparison with the positive control in which the two chambers are separated by the same type of semi-permeable membrane without the barrier created by the sample. 4.1 PREPARATION OF THE CELL CULTURE: For each assayed sample (as per 2. above), HuDe line cells were seeded in the wells of a cell culture plate, one for the barrier assay (T.B.) (BA) and another one for the internal control at a density of 40,000 cells/ml in MEM medium supplemented with 10% bovine serum (FBS); 1 ml of cell suspension per well.
The cells were treated with the SAMPLE (CAM), with the POSITIVE CONTROL (C+) (inflammatory agent without sample), and with the NEGATIVE CONTROL (C−) (medium only) and each assay was carried out in triplicate.
The plates were incubated at 37°C, overnight (22-24 hours). 4.2 PREPARATION OF INSERTS FOR COMPLEX CELL CULTURES Cell Culture Inserts (Becton Dickinson) for complex cell cultures were placed on other plates, and on each of them a fixed amount of collagen of 0.1 mg/ml was supplied. The plates were incubated at 37°C, overnight (22-24 hours).
In order to proceed with the experiment, a confluency not lower than 95% is expected.
From the two plates (BA and IC) with the inserts the collagen was removed, and the inserts were left under the flow of the hood for the time required to let them dry completely (10÷15 minutes). 4.3 BARRIER ASSAYS (BA) The steps described below were carried out in the culture plate for the BA.
Setting up of the sample layer in the BA: On the semi-permeable membrane of the sample, 100µl of a composition based on 0.5% alginate were inoculated and allowed to stratify for 20 minutes, while in the C+ and C– inserts nothing was added. Once the 20 minutes had elapsed, excess sample was eliminated, and the membranes washed with PBS according to procedures specified by the protocol.
Addition of LPS (inflammatory agent) to BA inserts Once the sample layer had dried, as per example at 2. above, in the first three CAM inserts and in the three C+ ones, 300µl of the LPS (membrane lipopolysaccharide) solution were inoculated at the concentration of 1µg/ml, while in the remaining three of the C- 300 µl of MEM medium with 5% FBS were added. The inserts were inserted in their respective wells with the cells and the plates were incubated for 1 h at 37°C and under an atmosphere enriched with 5% CO2 overnight (22-24 hours).
Once completed the 1 h incubation, the inserts were removed and discarded, and the plates were incubated again overnight (22-24 hours). 4.4 INTERNAL CONTROL (IC) ASSAY: The internal control assay was carried out concomitantly with the BA.
Exposure of IC cells to LPS: Once dried, in the first six inserts of IC, three for the sample to be analyzed, CAM, and three for the C+, 300µl of the LPS solution were inoculated, while in the remaining three of the C- 300µl of the medium were added.
The inserts with LPS and MEM were then inserted in the wells with IC cells and all incubated for 1 h.
LPS removal and IC membrane drying: Once completed the 1 h incubation, the inserts were removed from the wells with the cells and transferred to the empty plate, while the plate with the cells was placed in an incubator.
The LPS solution still present was removed from the inserts, the latter were subjected to a rapid wash with ultrapure sterile water and allowed to dry.
Arrangement of sample layer in the IC: On the semi-permeable membrane of the three inserts for the sample, 100µl of a composition based on 0.5% alginate were inoculated and allowed to stratify for 20 minutes, while in the C+ and C– inserts nothing was added. Once the 20 minutes had elapsed, the excess sample was eliminated, and the membranes were washed with PBS according to procedures specified by the protocol.
Addition of LPS to IC inserts Once the inserts with the sample were ready, 300 µl of medium were added to all inserts (CAM, C+, C-). The inserts were inserted in their respective wells with the cells and the plates incubated for 1 h at 37°C.
Once completed the 1 h incubation, the inserts were removed and discarded, and the plates incubated again overnight (22-24 hours). 4.5 SUPERNATANT COLLECTION AND ENZYME IMMUNOASSAY Once the 22-24 hours had elapsed, the supernatants were collected from the BA and the IC plates for performing the ELISA assay and the semi-quantitative dosage of IL-6.
BARRIER EFFECT (BE) ASSESSMENT The BE of a substance or compound is expressed as % reduction in the release of IL-6 cytokine by cells exposed to LPS wherein the sample has been assayed relative to the positive control (C+) wherein the cells have only been exposed to LPS.
BE = % reduction in release of IL-6 cytokine = 100 - [ (pg/µL cytokine released from sample / pg/µL cytokine released from C +) x 100] As can be seen from the results in Figures 1- 4, the composition of the invention has excellent mucoadhesive properties and a high barrier effect.
Apparently, therefore, beside free radical scavenger activity and stability over time, the composition also has barrier effect and high mucoadhesive properties.
. PREPARATION OF FRACTIONS 1. Example of preparation of polysaccharide (mucilage) fraction of Marshmallow Dried and crumbled marshmallow root is subjected to extraction by water, in a static extractor by percolate digestion, with the plant immersed in solvent and the solvent recycled bottom-to-top by a mechanical pump.
The drug-solvent ratio (DSR) is equal to 1:10, extraction temperature is of 90°C, extraction length is 12 hours. From the resulting mixture, the insoluble residue is separated from the soluble fraction by static decanting and subsequently by filtration on paper filter. The resulting solution is concentrated by ethanol evaporation, by use of a vacuum concentration system. Upon reaching a degree of concentration of :1, concentration is discontinued, and drying is completed by lyophilization or spray drying. The lyophilized material constitutes the fraction of interest (DER 4- :1). 2. Example of preparation of polysaccharide fraction of plantain Dried and crumbled plantain leaves are subjected to extraction by ethanol 50% (ethanol:water 50:50 v/v), in a static extractor by percolate digestion, with the plant immersed in solvent and the solvent recycled bottom-to-top by a mechanical pump.
The drug-solvent ratio (DSR) is equal to 1:10, extraction temperature is of 50°C, extraction length is 6-8 hours. From the resulting mixture, the insoluble residue is separated from the soluble fraction by static decanting and subsequently by filtration on paper filter. The resulting solution is concentrated by ethanol evaporation, by use of a vacuum concentration system. Upon reaching a degree of concentration of :1, concentration is discontinued, and drying is completed by lyophilization or spray drying. The lyophilized material constitutes the fraction of interest (DER 4- :1). 3. Example of preparation of polyphenolic fraction of Agrimony Dried and crumbled agrimony tops are subjected to extraction by water, in a static extractor by percolate digestion, with the plant immersed in solvent and the solvent recycled bottom-to-top by a mechanical pump.
The drug-solvent ratio (DSR) is equal to 1:8, extraction temperature is of 90°C, extraction length is 12 hours. From the resulting mixture, the insoluble residue is separated by static decanting and subsequently by filtration on paper filter. From the resulting mixture, the insoluble residue is separated from the soluble fraction by static decanting and subsequently by filtration on paper filter. The resulting solution is concentrated by ethanol evaporation, by use of a vacuum concentration system.
Upon reaching a degree of concentration of 10:1, concentration is discontinued, and drying is completed by lyophilization or spray drying. The lyophilized material constitutes the fraction of interest (DER 4-10:1).
Claims (10)
1. Use of a composition comprising one or more polysaccharide fractions of 5 plantain, one or more polysaccharide fractions of marshmallow, one or more polyphenolic fractions of agrimony comprising tannins, brown sugar, honey and one or more pharmaceutically acceptable carriers and/or excipients wherein said one or more polyphenolic fractions of agrimony comprising tannins comprises polyphenols at a percentage in weight greater than or equal to 3% in the manufacture of a 10 medicament for the treatment of cough.
2.The use according to claim 1, wherein said one or more polysaccharide fractions of plantain comprises polysaccharides having a molecular weight higher than 20000 Daltons at a percentage in weight greater than or equal to 3%.
3. The use according to claim 1 or according to claim 2, wherein said one or more polysaccharide fractions of marshmallow comprises polysaccharides having a molecular weight higher than 20000 Daltons at a percentage in weight greater than or equal to 5%.
4. The use according to any one of claims 1 to 3, wherein said excipients are selected from natural flavourings, preservatives, thickening agents.
5. The use according to claim 4, wherein said one or more natural flavourings, 25 preservatives, thickening agents are selected from lemon juice, blackberry juice, natural orange flavour, natural lemon flavour, natural myrtle flavour, xanthan gum.
6. The use according to any one of claims 1 to 5, wherein said extracts are in lyophilized or spray dried form.
7. The use according to any one of claims 1 to 6, wherein the composition is in the form of tablet, pill, granules, powder, syrup, elixir, hard gelatin, soft gelatin, suspension, spray, emulsion, solution. 35
8. The use according to any one of claims 1 to 7, wherein the composition is characterized in that it has a percentage of mucoadhesion, measured with a lectin binding inhibition of between 85% and 50% when not diluted or diluted up to a maximum of 1:5. 5
9. The use according to any one of claims 1 to 8, wherein said treatment is a treatment for dry cough, productive cough, cough associated with URTI (upper respiratory tract infections), cough from post-nasal drip.
10. A process for the preparation of a composition consisting of polysaccharide 10 fraction/s of plantain, fraction/s polysaccharide of marshmallow, polyphenolic fraction/s comprising tannins of agrimony, brown sugar, honey and one or more of pharmaceutically acceptable carriers and excipients, wherein polysaccharide fraction/s of plantain, polysaccharide fraction/s of marshmallow, polyphenolic fraction/s of agrimony comprising tannins are mixed with honey, brown sugar and 15 one or more pharmaceutically acceptable excipients and carriers wherein said one or more polyphenolic fractions of agrimony comprising tannins comprises polyphenols at a percentage in weight greater than or equal to 3%. Aboca S.p.A. Società Agricola 20 Patent Attorneys for the Applicant/Nominated Person SPRUSON & FERGUSON
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102017000016964A IT201700016964A1 (en) | 2017-02-15 | 2017-02-15 | COMPOSITION FOR COUGH |
IT102017000016964 | 2017-02-15 | ||
PCT/IB2018/050837 WO2018150309A1 (en) | 2017-02-15 | 2018-02-12 | Composition for cough |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ754291A NZ754291A (en) | 2021-09-24 |
NZ754291B2 true NZ754291B2 (en) | 2022-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018220880B2 (en) | Composition for cough | |
CA2928551C (en) | Composition for use in the treatment of cough | |
KR100699790B1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a Lonicera caerulea L. var. edulis extract | |
KR101700348B1 (en) | Composition for Anti-Arthritis Using a Leaf or Fruit Extract of Litsea japonica | |
EP2996703B1 (en) | Senna extracts and uses thereof | |
NZ754291B2 (en) | Composition for cough | |
US20100074975A1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea L. Var. Edulis extract | |
AU2015220485B2 (en) | Fractions of extracts of Helichrysum having mucohadesive properties | |
EA042160B1 (en) | COUGH TREATMENT COMPOSITION | |
KR102090133B1 (en) | Composition comprising Hibiscus syriacus L. extract for caring damages of skin cells by microdust | |
WO2018226060A1 (en) | Composition for preventing or treating kidney disease including cudratricusxanthone a having kidney-protecting activity as active ingredient | |
WO2022119352A1 (en) | Antitussive and mucoactive composition comprising extract of hibiscus syriacus l. as active ingredient | |
Shimode et al. | Antiglycative effect and Antiviral effect of Kuromoji (Lindera umbellata Thunb.) extract. | |
RU2321419C1 (en) | DRY TABLETTED FORMULATION OF Cetraria islandica (L.) Ach. EXTRACT | |
KR20180005435A (en) | Composition for improving constipation or intestinal function |